Johnson & Johnson Q1 2026 Earnings Expected April 14

Johnson & Johnson is expected to release its Q1 2026 earnings results before the market opens on Tuesday, April 14. Analysts predict the company will report earnings of $2.68 per share and revenue of $23.6038 billion for the quarter.

The company will host a conference call to discuss the Q1 2026 results on Tuesday, April 14 at 8:30 AM ET. Johnson & Johnson reported earnings of $2.46 per share and revenue of $24.28 billion in its most recent quarter. Analysts expect Johnson & Johnson to post full-year 2026 earnings of $11 per share.

Among the pharma bigwigs that have reported results, Johnson & Johnson reported strong fourth-quarter results, beating estimates for both earnings and sales. The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a handful of pharma and biotech companies scheduled to report over the next two weeks.

Per the Earnings Trends report, as of Feb. 11, 73.3% of the companies in the Medical sector — representing 91% of the sector's market capitalization — reported quarterly earnings. Of these, 86.4% exceeded both earnings and sales estimates. Earnings decreased 1% year over year, while revenues increased 10.7%.

Fourth-quarter earnings in the medical sector are expected to decrease 0.6%, while sales are projected to rise 10.4% from the year-ago quarter. Johnson & Johnson is one of the largest and most famous companies in the pharmaceutical industry, with specializations ranging from the production of pharmaceuticals to medical device and consumer health products.

The company has a long history of dividend increases spanning 62 years and currently holds a payout ratio of 64%, one of the lowest in its peer group. Investors and analysts will be closely watching Johnson & Johnson's Q1 2026 earnings report and conference call for insights into the company's financial performance, product pipeline, and outlook for the rest of the year.